Uveitis Therapeutics Market Size, Share and Analysis by Uveitis Type (Anterior, Intermediate, Posterior, Panuveitis), By Drug Class (Anti-inflammatory Medications, Antibiotic and Antivirals, Immunosuppressive Medications), By Route of administration(Oral, Intraocular, Intravenous), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2025-2032

Uveitis is an inflammatory condition of the eye resulted from idiopathic reasons, including infection or autoimmune disease. Redness, ocular ache, decreased vision, and photophobia is some of the symptoms associated with uveitis. Uveitis is prevalent worldwide and mostly affects the population of the age group 20 -40 years old. Based on the site of infection uveitis can be classified into anterior, intermediate, posterior, and panuveitis. When inflammation is seen in the iris and ciliary body it is known as anterior uveitis and is the most common form of uveitis observed in western countries. Intermediate uveitis occurs when inflammation is seen in the ciliary body that causes floaters and blurred vision. According to the Northern California Epidemiology Study, it has been estimated that around 1.5 per 100,000 population are affected by intermediate uveitis each year.

When inflammation is observed in the choroid region it leads to posterior uveitis. Diffuse uveitis or panuveitis occurs when inflammation is seen in the whole area of the uvea. Uveitis can be treated based on severity by using different dosage forms either through injections, eye drops or oral medications. Corticosteroids are considered as the first line of therapy for treating uveitis. Many immunomodulatory or immunosuppressor drugs and antimicrobial and antibiotic therapy are currently used to treat uveitis. For instance, in 2018, AbbVie Inc. manufactured adalimumab an anti-TNF-α monoclonal antibody received FDA approval for the treatment of non-infectious intermediate, posterior, and panuveitis in patients 2 years of age and older. 

To gain extensive insights into the market, Download for Customization

Growth in uveitis therapeutics market is driven mainly by the growing prevalence of uveitis globally, rise in the geriatric patient population, and high expenditure in research and development activity. In addition, effective pipeline drugs and growing awareness about the available treatment options by healthcare domains are likely to enhance the growth in uveitis therapeutics market in the forecasting period.

On the contrary, the high cost of care of patients with uveitis and possible side effects related to the drugs such as tremors, reversible hypertension, etc. are likely to hamper the uveitis therapeutics market in the forecasting period. 

Key Players Covered

Some of the major companies that are present in the global brain cancer therapeutics market include Bausch & Lomb Incorporated., ALLERGAN, Santen Pharmaceutical Co., Ltd., Novartis AG, Strides Pharma Science Limited., Panacea Biotec Ltd.,Merck & Co., Inc., OphthaliX Inc., Alimera Sciences, Enzo Biochem Inc., and others 

SEGMENTATION 

In terms of drugs class, Immunosuppressive medications which include biologics are considered more safe and effective thus anticipated to enhance the growth in uveitis therapeutics in the forecasting period. 

Key Insights 

• Overview of Pipeline Therapies
• Global Epidemiology Analysis of Uveitis
• Overview of A Novel Drug Delivery System for Uveitis Treatment
• The Regulatory Scenario for Key Countries/Regions
• Key Industry Developments - Mergers, Acquisitions, and Partnerships  

Regional Analysis

Geographically, the global uveitis therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to dominate the market in forecasting period owing to growing expenditure in the healthcare sector to developed new molecules to treat uveitis and high adoption of treatment for uveitis. Asia Pacific is anticipated to expand at the significant growth rate in the uveitis therapeutics market during the forecast period due to the growing patient population, increasing demand of therapies to treat uveitis, and raising awareness about the treatment options for uveitis by healthcare regulatory bodies. 

Key Industry Developments 

• In October 2018, EyePoint Pharmaceuticals received FDA approval to use YUTIQ a fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
• In July 2016, Infliximab and adalimumab (Humira) manufactured by AbbVie Inc. were the first and only biologic that received FDA approval for treatment of uveitis.